Non-Fucosylated Anti-Human HER2 (v10000) Therapeutic Antibody (CAT#: BioBet-1718ZP) Datasheet

ERBB2

erb-b2 receptor tyrosine kinase 2

This gene encodes a member of the epidermal growth factor (EGF) receptor family of receptor tyrosine kinases. This protein has no ligand binding domain of its own and therefore cannot bind growth factors. However, it does bind tightly to other ligand-bound EGF receptor family members to form a heterodimer, stabilizing ligand binding and enhancing kinase-mediated activation of downstream signalling pathways, such as those involving mitogen-activated protein kinase and phosphatidylinositol-3 kinase. Allelic variations at amino acid positions 654 and 655 of isoform a (positions 624 and 625 of isoform b) have been reported, with the most common allele, Ile654/Ile655, shown here. Amplification and/or overexpression of this gene has been reported in numerous cancers, including breast and ovarian tumors. Alternative splicing results in several additional transcript variants, some encoding different isoforms and others that have not been fully characterized.

NEU; NGL; HER2; TKR1; CD340; HER-2; MLN 19; HER-2/neu

Protein Based Therapies
Monoclonal antibody (mAb)

IgG

v10000

Human

Human

v10000 induces ADCC of HER2 2+ ZR-75-1 breast cancer cells with maximal cell lysis about 1.3 times greater than Herceptin, and nonfucosylated v10000 It has been shown to induce maximal cell lysis about 1.5 times greater than Herceptin.

HER2-positive breast cancer; metastatic breast cancer

10154